Eli Lilly and Company

🇺🇸New York Stock Exchange
Back to all articles
Eli Lilly and Company stock analysis LLY overview
Bullish +75

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader

📈 Eli Lilly reported $19.29 billion in Q4 revenue, representing a 42.6% year-over-year increase driven primarily by its weight loss franchise.

💰 Mounjaro generated $7.41 billion in Q4 with an 110% surge, while Zepbound contributed $4.26 billion and grew 123%.

🚀 Lilly’s tirzepatide is driving volume growth of 46% despite a slip in realized prices due to market conditions.

📉 Novo Nordisk saw Q4 revenue decline by 7.6%, with U.S. operations specifically falling 15% year-over-year.

🔨 Novo cut approximately 9,000 jobs and incurred $8 billion in one-off charges during 2025 to address declining sales.

💉 Novo’s Wegovy injectable offers roughly 14% body weight reduction compared to Lilly’s tirzepatide at 20%.

📝 Novo launched an oral Wegovy pill in January 2026, generating around 50,000 weekly prescriptions across 70,000 pharmacies.

💊 Lilly’s oral candidate orforglipron submitted for approval in the U.S., Japan, and EU following Phase 3 data outperforming oral semaglutide.

🧬 Retatrutide, Lilly's triple agonist, demonstrated up to 71.2 lbs of weight loss during Phase 3 trials.

🏭 Lilly is expanding manufacturing capacity in Alabama, Pennsylvania, and Europe with over $50 billion in U.S. investment commitments.

⚠️ Novo faces structural pricing pressures from the Most Favoured Nations agreement and impending patent expiries.

🩺 Novo’s diabetes market share declined 3.6 percentage points to 30.1% as competitors gain ground.

💰 Lilly trades at a 27x forward P/E multiple compared to Novo Nordisk's 11x forward earnings multiple.

📉 Novo Nordisk saw its stock price decline 39.85% over the past year while Lilly gained 27.65%.

🏥 A Medicare coverage expansion could add roughly 15 million eligible patients to the obesity drug market in 2026.

💡 Novo’s CagriSema is submitted to the FDA for weight management, awaiting differentiated efficacy data.

📉 Lilly’s pipeline depth and manufacturing scale provide a growth edge despite its higher premium valuation.

👀 Market attention will focus on whether orforglipron approval by mid-2026 undercuts Novo's newly launched oral pill.

💼 Novo Nordisk generates enormous cash flow but faces multi-year headwinds from pricing and patent dynamics.

🏦 Lilly trades at a 4x higher forward multiple, reflecting investors' confidence in its execution and growth trajectory.

📉 Novo’s dividend yield stands at 4.88%, potentially appealing to value investors waiting for clinical or coverage catalysts.

Bullish Signals
  • Liily's fourth quarter revenue reached $19.29 billion, representing a 42.6% year-over-year increase driven by its strong tirzepatide franchise.
  • Mounjaro generated $7.41 billion in Q4 (up 110%), while Zepbound added $4.26 billion (up 123%), demonstrating powerful growth from two core products.
  • Tirzepatide's dual GIP/GLP-1 mechanism delivers roughly 20% body weight reduction in trials, outperforming Novo's Wegovy at approximately 14%.
  • Lilly is building manufacturing at scale with new facilities in Alabama, Pennsylvania, and Europe, alongside commitments to exceed $50 billion in U.S. manufacturing investment since 2020.
  • Orforglipron has been submitted for approval in the U.S., Japan, and EU, with Phase 3 data showing it outperformed oral semaglutide in a head-to-head trial.
  • Retatrutide, a triple agonist developed by Lilly, showed weight loss of up to 71.2 lbs in Phase 3 trials, showcasing deep pipeline efficacy.
  • If Lilly receives orforglipron approval in the U.S. by mid-2026, it enters the oral market with a product that has already beaten oral semaglutide in a head-to-head trial.
  • Lilly trades at a 27x forward P/E, reflecting strong growth momentum and a business executing at a high level.
  • Lilly's one-year price gain of 27.65% reflects a business executing at a high level while Novo's 39.85% one-year decline reflects genuine structural concern.
Risk Factors
  • Novo Nordisk's fourth quarter revenue declined 7.6% year-over-year, with U.S. operations falling an even steeper 15%.
  • Operating income slipped 0.53% as costs tightened, indicating underlying profitability pressures despite full-year sales growth in DKK.
  • CEO Mike Doustdar warned that in 2026, Novo Nordisk will face pricing headwinds in an increasingly competitive market.
  • The company cut roughly 9,000 jobs and absorbed approximately $8 billion in one-off charges during 2025, signaling significant cost reduction efforts.
  • Novo faces structural pricing pressure from its Most Favoured Nations agreement with the U.S. administration and semaglutide patent expiry in select international markets.
  • The company's diabetes value market share declined 3.6 percentage points to 30.1%, reflecting competitive erosion in its core segment.
  • Novo Nordisk's stock is down 39.85% over the past year, with a forward P/E of 11x reflecting genuine structural concern compared to competitors.
  • Lilly's new oral tirzepatide (orforglipron) has already outperformed oral semaglutide in head-to-head trials, potentially putting Novo's oral Wegovy pill under immediate competitive pressure upon its January 2026 launch.
Full Analysis
Eli Lilly and Company (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) reported contrasting quarterly results in early February that have widened the competitive gap between the two giants in the obesity drug market. Lilly's fourth-quarter revenue surged to $19.29 billion, representing a 42.6% year-over-year increase, driven almost exclusively by its tirzepatide franchise with Mounjaro revenue jumping 110% to $7.41 billion and Zepbound rising 123% to $4.26 billion. This growth occurred despite a realized price headwind where prices slipped while volume expanded 46%, whereas Novo Nordisk's Q4 revenue declined 7.6% year-over-year, with U.S. operations specifically falling 15%. Full-year sales in DKK for Novo grew 6.43%, but operating income slipped 0.53% as the company tightened costs to manage the decline. In response to pricing headwinds and increased competition, Novo Nordisk acknowledged that 2026 will face significant challenges in an increasingly competitive market. To stabilize its position, the Danish pharmaceutical company cut approximately 9,000 jobs and absorbed roughly $8 billion in one-off charges during 2025. CEO Mike Doustdar noted a shift in strategy towards a newly launched oral pill, Wegovy, which began distribution in January 2026 across over 70,000 pharmacies and is currently generating about 50,000 weekly prescriptions at a starter dose of $149 per month. Novo faces further structural pressure from its Most Favoured Nations agreement with the U.S. administration and impending semaglutide patent expiry in select international markets, which contributed to a diabetes value market share decline of 3.6 percentage points to 30.1%. Conversely, Lilly is leveraging superior weight loss efficacy and an advanced pipeline. Tirzepatide’s dual GIP/GLP-1 mechanism achieves roughly 20% body weight reduction in trials compared to approximately 14% for Novo's Wegovy. Lilly also possesses a robust oral pipeline with orforglipron submitted for approval in the U.S., Japan, and EU after demonstrating it outperformed oral semaglutide in head-to-head trials, and retatrutide, a triple agonist, which showed weight loss of up to 71.2 lbs in Phase 3. Additionally, Lilly is scaling manufacturing significantly with new facilities planned in Alabama, Pennsylvania, and Europe, backed by commitments to exceed $50 billion in U.S. manufacturing investment since 2020. Investors note that if Lilly receives orforglipron approval in the U.S. by mid-2026, it would enter the oral market with a product already proven superior to Novo's semaglutide equivalent. The disparity is reflected starkly in their valuations and stock performance, with Lilly trading at a 27x forward P/E compared to Novo Nordisk's 11x forward earnings over the past year, reflecting a one-year price gain of 27.65% for Lilly versus a 39.85% decline for Novo. While Lilly is viewed as executing at a high level with deep pipeline depth and manufacturing buildout, Novo's direction concerns analysts due to genuine structural concerns regarding pricing pressure and patent dynamics. Novo Nordisk still generates enormous cash flow and offers a dividend yield of 4.88%, which may appeal to value investors awaiting potential catalysts such as CagriSema efficacy data or Medicare coverage expansion for obesity drugs that could add roughly 15 million eligible patients to the market.